Molecular Partners AG (MLLCF)

3,8000 0,0000 (0,00%) Ab 11:37AM EDT. Markt geöffnet.

Molecular Partners AG

Wagistrasse 14
Schlieren 8952
Switzerland
41 44 755 77 00
https://www.molecularpartners.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 167

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Patrick Amstutz Ph.D.	Co-Founder, CEO, Member of Management Board & Director	723,83k	N/A	1975
Dr. Michael Tobias Stumpp Ph.D.	Co-Founder, Executive VP of Projects & Member of Management Board	N/A	N/A	1972
Mr. Robert Hendriks	Senior VP of Finance	N/A	N/A	N/A
Mr. Alexander Zurcher	COO & Member of Management Board	N/A	N/A	1975
Ms. Renate Gloggner	Executive VP of People & Community and Member of Management Board	N/A	N/A	1970
Mr. Daniel Steiner Ph.D.	Senior Vice President of Research & Technology	N/A	N/A	N/A
Mr. Seth D. Lewis	Senior Vice President of Investor Relations, Communications & Strategy	N/A	N/A	N/A
Mr. Michael Pitzner	General Counsel, Compliance Officer, Senior VP Legal & Business Development	N/A	N/A	N/A
Dr. Pamela A. Trail Ph.D.	Strategic Consultant	N/A	N/A	1956
Ms. Anne Goubier D.V.M., Ph.D.	Senior Vice President of Research & Early Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Corporate Governance

Molecular Partners AGs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.